Iron Octasaccharide Complexes for Companion Animal Therapy
Summary
USPTO published patent application US20260108551A1 on April 23, 2026, covering iron octasaccharide complexes for subcutaneous administration in methods of treating iron deficiency, particularly iron deficiency anaemia, in companion animals. The application, originally filed August 3, 2022, names three inventors: Hans B. Andreasen, Tobias S. Christensen, and Simon M. Guldberg. The invention extends to pharmaceutical compositions comprising an iron octasaccharide complex and a pharmaceutically acceptable carrier for veterinary therapeutic use.
“The present invention relates to iron complex compounds for subcutaneous use in a method of therapy, e.g., for iron deficiency, particularly of iron deficiency anaemia, in a companion animal and to pharmaceutical compositions for subcutaneous administration, comprising an iron complex compound and a pharmaceutically acceptable carrier.”
About this source
USPTO classification A61K covers pharmaceutical preparations: formulations, dosage forms, combination therapies, delivery systems, and the vehicles that carry active ingredients. Every newly published application in A61K lands in this feed, around 245 a month. Applications publish 18 months after filing, so this feed reveals what pharma formulators at major sponsors and generics were working on in the prior year and a half. Watch this if you compete in drug formulation, file freedom-to-operate analyses, scout competitive drug products before clinical readouts, or follow novel delivery platforms like nanoparticles, lipid carriers, and long-acting injectables.
What changed
USPTO published patent application US20260108551A1 disclosing iron octasaccharide complex compounds and pharmaceutical compositions for subcutaneous administration in methods of treating iron deficiency, particularly iron deficiency anaemia, in companion animals and human subjects. The application covers both the iron complex compounds themselves and their use in therapeutic methods.
Pharmaceutical manufacturers and veterinary drug developers researching iron deficiency treatments for companion animals should monitor this application to assess potential freedom-to-operate considerations or licensing opportunities for iron octasaccharide-based therapeutics.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
IRON COMPLEX COMPOUNDS FOR SUBCUTANEOUS USE IN THERAPY OF IRON DEFICIENCY IN COMPANION ANIMALS
Application US20260108551A1 Kind: A1 Apr 23, 2026
Inventors
Hans B. ANDREASEN, Tobias S. CHRISTENSEN, Simon M. GULDBERG
Abstract
The present invention relates to iron complex compounds for subcutaneous use in a method of therapy, e.g., for iron deficiency, particularly of iron deficiency anaemia, in a companion animal and to pharmaceutical compositions for subcutaneous administration, comprising an iron complex compound and a pharmaceutically acceptable carrier. The present invention relates more particularly, although not exclusively, to iron octasaccharide complexes, pharmaceutical compositions comprising an iron octasaccharide complex, and the iron octasaccharide complexes for use in a method of therapy of iron deficiency, particularly of iron deficiency anaemia, in a human or non-human subject.
CPC Classifications
A61K 31/715 A61K 9/0021 A61P 7/06
Filing Date
2022-08-03
Application No.
18294572
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.